Company

Genentech's Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC
CancerClinical trial results

Genentech’s Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), announced pivotal results from the Phase III Krascendo 1 study, demonstrating that investigational next‑generation KRAS G12C inhibitor divarasib showed…

HutchMed's Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

HutchMed’s Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

FDA Approves At‑Home Subcutaneous Induction Regimen for AbbVie's Skyrizi (Risankizumab) in Moderately to Severely Active Crohn's Disease – On‑Body Injector Enables Treatment Start at Home

FDA Approves At‑Home Subcutaneous Induction Regimen for AbbVie’s Skyrizi (Risankizumab) in Moderately to Severely Active Crohn’s Disease – On‑Body Injector Enables Treatment Start at Home

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
Clinical trial approval / initiationEverest Medicines

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer
ADC / XDCHKG: 6990

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621
ADC / XDCBeihai Biotech

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC
ADC / XDCBiokin Pharmaceutical

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Show More